Financials

Total revenue
Net income
Basic earnings per share (Basic EPS)
Total debt
Free cash flow
Cash & equivalents
Price to earnings ratio
46.83
Price to sales ratio
14.83
Dividends per share
6.23
Dividend yield %
0.58

Related tickers

#NamePrice24h %7d %1M %1Y %Market CapLast 7 Days
20
JNJ
Johnson & Johnson Common Stock
261.49 USD+1.95%+2.30%-3.47%+37.87%630.16 B USD
24
ABBV
AbbVie Inc. Common Stock
276.48 USD+1.49%+5.53%+4.84%+20.21%488.57 B USD
35
MRK
Merck & Company, Inc. Common Stock
145.57 USD+2.23%+1.58%-0.84%+69.96%359.15 B USD
48
NVS
Novartis AG
143.77 USD+0.45%+2.01%+1.50%+10.93%274.33 B USD

Frequently asked questions about Eli Lilly & Co.

What is the Eli Lilly & Co. stock price today?

The current price of Eli Lilly & Co. (LLY) is 1178.70. Over the past 24 hours, the stock has changed by +0.75%. Follow the LLY chart for real-time price dynamics.

What is the stock ticker of Eli Lilly & Co.?

Eli Lilly & Co. trades under the ticker LLY. Tickers can differ by exchange, so always check the exchange and instrument details before trading.

Is Eli Lilly & Co. stock going up?

LLY has changed by +2.41% over the last week, +3.20% over the last month, and +42.01% over the last year. Review the chart to see whether the current move is part of a broader trend.

What is the market capitalization of Eli Lilly & Co.?

Eli Lilly & Co. currently has a market capitalization of 1.11 T. Market capitalization reflects the total market value of a company's outstanding shares and is commonly used to compare companies by size.

Does Eli Lilly & Co. release financial reports?

Yes. You can track Eli Lilly & Co. financial reports and review yearly or quarterly fundamentals on metatrader.com, including revenue, net income, dividends, and valuation metrics.

What were Eli Lilly & Co. earnings last quarter?

Last quarter, Eli Lilly & Co. reported earnings of 7.95 per share. Earnings per share is one of the key metrics investors use to evaluate a company's profitability and financial performance.

What was Eli Lilly & Co. revenue for the last quarter?

Eli Lilly & Co. reported quarterly revenue of 22.97 B. Revenue is one of the main indicators used to evaluate the company's business growth and operating scale.

What was Eli Lilly & Co. net income for the last quarter?

Eli Lilly & Co. reported net income of 7.09 B for the last quarter. The previous quarter showed 7.4 B, which means net income changed by -4.07%.

Does Eli Lilly & Co. pay dividends?

Eli Lilly & Co. paid a dividend per share of 3.46. The current dividend yield is 1.31%. Dividend data can help income-focused investors evaluate the stock.

How many employees does Eli Lilly & Co. have?

As of the latest available data, Eli Lilly & Co. has 50 K employees. Workforce size can provide additional context about the company's scale and operations.

What is Eli Lilly & Co. EBITDA?

Eli Lilly & Co. EBITDA is 9.51 B, and its EBITDA margin is 41.4%. EBITDA is commonly used to evaluate operating performance before interest, taxes, depreciation, and amortization.

How can I buy Eli Lilly & Co. stock?

You can buy Eli Lilly & Co. (LLY) through a broker that provides access to the relevant stock exchange. Before trading, check commissions, execution conditions, account type, and whether the stock fits your investment plan.

Should I invest in Eli Lilly & Co. stock?

Investing in Eli Lilly & Co. requires reviewing its financial statements, valuation, earnings outlook, news, technical picture, and market risks. Use the LLY chart and related analysis on metatrader.com as part of your research.

Eli Lilly and Company Common Stock

Eli Lilly and Company, doing business as Lilly, is an American multinational pharmaceutical company headquartered in Indianapolis, Indiana, with offices in 18 countries. Its products are sold in approximately 125 countries. The company was founded in 1876 by Eli Lilly, a pharmaceutical chemist and Union army veteran during the American Civil War for whom the company was later named. The company is ranked 4th on the list of largest biomedical companies by revenue and is the most valuable pharmaceutical company worldwide. It is ranked 100th on the Fortune 500 and 138th on the Forbes Global 2000. In November 2025, the company reached a $1 trillion market capitalization, the first health-care company in the world to do so. The company's primary products are tirzepatide for the treatment of type 2 diabetes, weight loss, and obstructive sleep apnea; abemaciclib for the treatment of advanced or metastatic breast cancers; dulaglutide for the treatment of type 2 diabetes; ixekizumab for the treatment of autoimmune diseases; and empagliflozin for the treatment of type 2 diabetes.

News